ONC Stock Gains As BeOne Medicines Wins U.S. Nod For BEQALZI In Rare Lymphoma

• Mantle cell lymphoma is a rare, aggressive form of non-Hodgkin lymphoma that affects roughly 3,300 new patients annually in the United States. 
• Continued approval will depend on confirmatory trials, BeOne said.
• Several popular drugs in the United States have successfully transitioned from the FDA’s accelerated approval pathway to full traditional approval after confirmatory trials.

BeOne Medicines (ONC) shares climbed nearly 2% Wednesday after the U.S. Food and Drug Administration granted accelerated approval to the company’s BEQALZI, marking the first new B-cell lymphoma 2 inhibitor approved in nearly a decade and the only one cleared for mantle cell lymphoma.

The approval covers adult patients with relapsed or refractory (R/R) mantle cell lymphoma who have received at least two prior lines of systemic therapy. BeOne, formerly BeiGene, described the drug as a next-generation BCL2 inhibitor engineered for greater potency, selectivity, and a pharmacologic profile that could improve efficacy, tolerability, and dosing convenience. BCL-2 inhibitors are a class of targeted cancer therapies that induce cancer cell death by blocking the BCL-2 protein, which otherwise allows cancer cells to evade self-destruction.

Mantle cell lymphoma is a rare, aggressive form of non-Hodgkin lymphoma that affects roughly 3,300 new patients annually in the United States.

ONC Approval Data

The accelerated approval was based on data from a study showing an overall response rate of 52% and a complete response rate of 16%, with a median duration of response of 15.8 months. The drug was generally well tolerated, the firm said.

Continued approval will depend on confirmatory trials, BeOne said. BEQALZI is already approved in China for this indication and is under review by the European Medicines Agency and other regulators.

Other Accelerated Approval Stories

Several popular drugs in the United States have successfully transitioned from the FDA’s accelerated approval pathway—granted on the basis of surrogate endpoints promising clinical benefit—to full traditional approval after confirmatory trials verified their efficacy and safety. High-profile examples include Merck’s Keytruda, which received accelerated approval in 2017 for microsatellite instability-high or mismatch repair-deficient solid tumors and was converted to full approval in 2023.

Yet another name is Bristol Myers Squibb’s Opdivo, accelerated in 2016 for relapsed or refractory classical Hodgkin lymphoma and granted traditional approval in March 2026.

How Did ONC Retail Traders React?

On Stocktwits, retail sentiment around ONC stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.

A Stocktwits user opined that the stock will “retest the highs” it touched earlier this year.

ONC stock has gained about 40% over the past 12 months. 

Read More: Nvidia Stock Draws Attention As Culper Research Takes Short Position Over China Ties

For updates and corrections, email newsroom[at]stocktwits[dot]com.